{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-260679","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-06-08T11:15:55+00:00","discovered_at":"2026-06-08T11:20:00.321110+00:00","generated_at":"2026-06-08T11:20:57.045600+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tango reports 92% ORR in PDAC with vopimetostat + daraxonrasib combo; plans Phase 3","bullets":["92% ORR (11/12) in PDAC with vopimetostat + daraxonrasib; 90% 6-month PFS; 100% DCR.","100% ORR (3/3) in NSCLC with same combination; all responses confirmed.","Vopimetostat + zoldonrasib showed 52% ORR (14/27) in PDAC; 74% 6-month PFS; 96% DCR.","Combinations well tolerated; no discontinuations due to AEs; no Grade 4/5 related AEs.","Company plans Phase 3 randomized-controlled trial in front-line pancreatic cancer in 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-260679","json":"https://secwatch.observer/filing/0001193125-26-260679.json","markdown":"https://secwatch.observer/filing/0001193125-26-260679.md","text":"https://secwatch.observer/filing/0001193125-26-260679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/0001193125-26-260679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/d158334d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:20:57.045600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}